AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35241538 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch from Cisplatin to Carboplatin/Paclitaxel
Number of subjects: 150
Study 35241538 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin
Number of subjects: 150
Study 35241538 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin/Paclitaxel
Number of subjects: 150
Study 33662760 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold water ingestion (COLD)
Number of subjects: 10
Study 33662760 — intervention group
Group type: EXPERIMENTAL
Intervention: L-menthol mouth rinse (MENT)
Number of subjects: 10
Study 33662760 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 10
Study 32202020 — intervention group
Group type: EXPERIMENTAL
Intervention: High monocyte-to-lymphocyte ratio (MLR) >0.49
Number of subjects: 528
Study 32202020 — intervention group
Group type: EXPERIMENTAL
Intervention: High lactate dehydrogenase (LDH)
Number of subjects: 528
Study 32202020 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (MLR or LDH high)
Number of subjects: 528
Study 32202020 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 (MLR-LDH high)
Number of subjects: 528
Study 35417442 — intervention group
Group type: EXPERIMENTAL
Intervention: Health coaching
Number of subjects: 0
Study 33068301 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin 5mg/day (n=40)
Number of subjects: 120
Study 33068301 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin 100mg/day (n=40)
Number of subjects: 120
Study 33068301 — intervention group
Group type: COMPARATOR
Intervention: Traditional antidiabetic therapy (Control, n=40)
Number of subjects: 120
Study 34421824 — intervention group
Group type: COMPARATOR
Intervention: Waist circumference (WC) ≥88 cm
Number of subjects: 8887
Study 34421824 — intervention group
Group type: COMPARATOR
Intervention: Waist-to-height ratio (WHtR) 2nd quartile
Number of subjects: 8887
Study 34421824 — intervention group
Group type: COMPARATOR
Intervention: Waist-to-height ratio (WHtR) 3rd quartile
Number of subjects: 8887
Study 34421824 — intervention group
Group type: COMPARATOR
Intervention: Waist-to-height ratio (WHtR) 4th quartile
Number of subjects: 8887
Study 34421824 — intervention group
Group type: COMPARATOR
Intervention: Body Mass Index (BMI) Class I Obese
Number of subjects: 8887
Study 34421824 — intervention group
Group type: COMPARATOR
Intervention: Body Mass Index (BMI) Class II Obese
Number of subjects: 8887
Study 34421824 — intervention group
Group type: COMPARATOR
Intervention: Body Mass Index (BMI) Class III Obese
Number of subjects: 8887
Study 32628781 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic instrumentation
Number of subjects: 39
Study 32628781 — intervention group
Group type: COMPARATOR
Intervention: Hand instrumentation
Number of subjects: 39
Study 36194619 — intervention group
Group type: COMPARATOR
Intervention: Oral Itraconazole 100 mg/day and topical Terbinafine hydrochloride 1%
Number of subjects: 78
Study 32965622 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual intercourse 3–4 times/week with symptomatic treatment
Number of subjects: 70
Study 32965622 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic treatment only, no sexual intercourse or masturbation
Number of subjects: 70
Study 32795778 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-mg apomorphine sublingual film (APL)
Number of subjects: 0
Study 32795778 — intervention group
Group type: COMPARATOR
Intervention: 2-mg subcutaneous Apo-go
Number of subjects: 0
Study 35869885 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (9 motivational interviews in Year 1, followed by 3 sessions between Years 1 and 3)
Number of subjects: 1020
Study 35869885 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 1020
Study 35869885 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 1020
Study 33786846 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based intervention promoting physical activity and reducing sedentary time
Number of subjects: 0
Study 32801193 — intervention group
Group type: EXPERIMENTAL
Intervention: Teleconference delivery of the Managing Fatigue intervention
Number of subjects: 582
Study 32801193 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet delivery of the Managing Fatigue intervention
Number of subjects: 582
Study 32801193 — intervention group
Group type: COMPARATOR
Intervention: In-person delivery of the Managing Fatigue intervention
Number of subjects: 582
Study 35119481 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib once daily plus pembrolizumab every 6 weeks plus TACE
Number of subjects: 950
Study 35119481 — intervention group
Group type: COMPARATOR
Intervention: Placebos plus TACE
Number of subjects: 950
Study 35119481 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib plus pembrolizumab plus TACE
Number of subjects: 950
Study 33530097 — intervention group
Group type: EXPERIMENTAL
Intervention: TAF/FTC+DTG
Number of subjects: 385
Study 33530097 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF/FTC+DTG
Number of subjects: 385
Study 33530097 — intervention group
Group type: COMPARATOR
Intervention: TDF/FTC/EFV
Number of subjects: 385
Study 35667734 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality Improvement (QI) package including training in essential newborn care and QI tools
Number of subjects: 54919
Study 35667734 — intervention group
Group type: COMPARATOR
Intervention: Control group (no QI package)
Number of subjects: 54919
Study 35667734 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (with QI package)
Number of subjects: 54919
Study 32616612 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra rapid lispro (URLi)
Number of subjects: 673
Study 32616612 — intervention group
Group type: COMPARATOR
Intervention: Lispro
Number of subjects: 673
Study 35087789 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for predicting overall survival (OS)
Number of subjects: 1641
Study 35045888 — intervention group
Group type: EXPERIMENTAL
Intervention: Ionic-iodine polymer complex (200 mg of elemental iodine) in encapsulated form
Number of subjects: 200
Study 35045888 — intervention group
Group type: EXPERIMENTAL
Intervention: Ionic-iodine polymer complex (200 mg of elemental iodine) in suspension syrup form
Number of subjects: 200
Study 35045888 — intervention group
Group type: EXPERIMENTAL
Intervention: Ionic-iodine polymer complex (200 mg of elemental iodine) in throat spray form
Number of subjects: 200
Study 35045888 — intervention group
Group type: COMPARATOR
Intervention: Standard care with placebo
Number of subjects: 200
Study 34327766 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified capecitabine plus irinotecan (mXELIRI)
Number of subjects: 650
Study 34327766 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil, leucovorin, and irinotecan (FOLFIRI)
Number of subjects: 650
Study 32682395 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine wound infusion by PCA pump
Number of subjects: 70
Study 32682395 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline wound infusion by PCA pump (Control)
Number of subjects: 70
Study 33756407 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill walking for 20 minutes
Number of subjects: 28
Study 33756407 — intervention group
Group type: COMPARATOR
Intervention: Control group walking for 20 minutes on a treadmill
Number of subjects: 28
Study 33022367 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephonic intervention with a stepped protocol of 6–12 phone calls over 1 year, delivered by a health educator.
Number of subjects: 812
Study 33022367 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (control group).
Number of subjects: 812
Study 34041935 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Number of subjects: 33
Study 34041935 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 33
Study 33886128 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab
Number of subjects: 119
Study 32072863 — intervention group
Group type: EXPERIMENTAL
Intervention: YouTube video with high perceived quality and popularity
Number of subjects: 707
Study 32072863 — intervention group
Group type: EXPERIMENTAL
Intervention: YouTube video with low perceived quality and popularity
Number of subjects: 707
Study 32072863 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who conducted an online search
Number of subjects: 707
Study 33433389 — intervention group
Group type: EXPERIMENTAL
Intervention: BF-CoCr stent
Number of subjects: 200
Study 33433389 — intervention group
Group type: COMPARATOR
Intervention: BF-SS stent
Number of subjects: 200
Study 33234646 — intervention group
Group type: EXPERIMENTAL
Intervention: MyCare intervention and standard mental health support
Number of subjects: 0
Study 33234646 — intervention group
Group type: COMPARATOR
Intervention: Standard mental health support
Number of subjects: 0
Study 35724443 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics intervention
Number of subjects: 37
Study 33287790 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma therapy
Number of subjects: 500
Study 33287790 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 500
Study 36217640 — intervention group
Group type: EXPERIMENTAL
Intervention: AH Plus sealer
Number of subjects: 60
Study 36217640 — intervention group
Group type: EXPERIMENTAL
Intervention: MTA Fillapex sealer
Number of subjects: 60
Study 36217640 — intervention group
Group type: EXPERIMENTAL
Intervention: GuttaFlow Bioseal sealer
Number of subjects: 60
Study 36217640 — intervention group
Group type: COMPARATOR
Intervention: Silicone oil (used)
Number of subjects: 60
Study 36217640 — intervention group
Group type: COMPARATOR
Intervention: No silicone oil (not used)
Number of subjects: 60
Study 34706172 — intervention group
Group type: EXPERIMENTAL
Intervention: Risankizumab (90 mg, subcutaneously once every 4 weeks)
Number of subjects: 214
Study 34706172 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 214
Study 32705393 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT) at 50% of maximal inspiratory pressure (MIP) for 4 weeks
Number of subjects: 14
Study 32705393 — intervention group
Group type: COMPARATOR
Intervention: Placebo training (Sham) at 5% MIP for 4 weeks
Number of subjects: 14
Study 33948911 — intervention group
Group type: EXPERIMENTAL
Intervention: Atogepant (60 mg) co-administered with Acetaminophen (1000 mg)
Number of subjects: 40
Study 33948911 — intervention group
Group type: EXPERIMENTAL
Intervention: Atogepant (60 mg) co-administered with Naproxen (500 mg)
Number of subjects: 40
Study 33948911 — intervention group
Group type: COMPARATOR
Intervention: Atogepant alone
Number of subjects: 40
Study 33948911 — intervention group
Group type: EXPERIMENTAL
Intervention: Atogepant co-administered with Acetaminophen
Number of subjects: 40
Study 33948911 — intervention group
Group type: EXPERIMENTAL
Intervention: Atogepant co-administered with Naproxen
Number of subjects: 40
Study 33948911 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 40
Study 32423038 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent exercise with remote guidance (ME)
Number of subjects: 60
Study 32423038 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 60
Study 34933308 — intervention group
Group type: EXPERIMENTAL
Intervention: Frame-based Gamma Knife radiosurgery
Number of subjects: 58
Study 34933308 — intervention group
Group type: COMPARATOR
Intervention: Mask-based Gamma Knife radiosurgery
Number of subjects: 58
Study 34384001 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg + Rosuvastatin (10 or 20 mg) SPC
Number of subjects: 125
Study 34384001 — intervention group
Group type: COMPARATOR
Intervention: Telmisartan 80 mg monotherapy
Number of subjects: 125
Study 32144515 — intervention group
Group type: EXPERIMENTAL
Intervention: Alvogyl
Number of subjects: 36
Study 32144515 — intervention group
Group type: COMPARATOR
Intervention: Absorbable gelatin sponge
Number of subjects: 36
Study 35151285 — intervention group
Group type: EXPERIMENTAL
Intervention: CCT and Supported Employment (SE)
Number of subjects: 116
Study 35151285 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 116
Study 33787645 — intervention group
Group type: EXPERIMENTAL
Intervention: Shen'ge formula (SGF)
Number of subjects: 130
Study 33787645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 32091599 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-nitrate vegetables + placebo pills
Number of subjects: 243
Study 32091599 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-nitrate vegetables + nitrate pills (300 mg nitrate)
Number of subjects: 243
Study 32091599 — intervention group
Group type: EXPERIMENTAL
Intervention: Leafy green vegetables containing 300 mg nitrate + placebo pills
Number of subjects: 243
Study 32091599 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (control)
Number of subjects: 243
Study 33035741 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE)
Number of subjects: 200
Study 33035741 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 200
Study 33035741 — intervention group
Group type: COMPARATOR
Intervention: Nonstarters (compared to treatment starters)
Number of subjects: 200
Study 36148513 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroll Safe program
Number of subjects: 86
Study 36148513 — intervention group
Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 86
Study 34229085 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavender oil inhalation for 15 min before dressing (Lavender‐15 Group)
Number of subjects: 108
Study 34229085 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavender oil inhalation for 60 min before dressing (Lavender‐60 Group)
Number of subjects: 108
Study 34229085 — intervention group
Group type: COMPARATOR
Intervention: Control Group inhaled jojoba (placebo) oil for 15 min before dressing
Number of subjects: 108
Study 34738961 — intervention group
Group type: EXPERIMENTAL
Intervention: Video debriefing with gaze overlay
Number of subjects: 0
Study 34738961 — intervention group
Group type: COMPARATOR
Intervention: Video debriefing without gaze overlay
Number of subjects: 0
Study 33143773 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese visceral adiposity index (CVAI) highest quartile
Number of subjects: 10304
Study 33143773 — intervention group
Group type: EXPERIMENTAL
Intervention: Per-sd increase in CVAI
Number of subjects: 10304
Study 33143773 — intervention group
Group type: EXPERIMENTAL
Intervention: Per-sd increase in CVAI change
Number of subjects: 10304
Study 33143773 — intervention group
Group type: COMPARATOR
Intervention: CVAI compared to four other obesity indices
Number of subjects: 10304
Study 32247297 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 47
Study 32247297 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 47
Study 34173078 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotary system ProGlider and ProTaper Next X1, X2 (PG-PTN)
Number of subjects: 30
Study 34173078 — intervention group
Group type: COMPARATOR
Intervention: Reciprocating system WaveOne Gold Glider and WaveOne Gold Primary (WOGG-WOG)
Number of subjects: 30
Study 34173078 — intervention group
Group type: EXPERIMENTAL
Intervention: Both systems (PG-PTN and WOGG-WOG)
Number of subjects: 30
Study 34521298 — intervention group
Group type: EXPERIMENTAL
Intervention: Hugan tablets
Number of subjects: 623
Study 34521298 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 623
Study 35511950 — intervention group
Group type: EXPERIMENTAL
Intervention: VITAL model (viral load-triggered, participant's preference-informed, eHealth-supported, automated differentiated service delivery model)
Number of subjects: 0
Study 35511950 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study 35511950 — intervention group
Group type: EXPERIMENTAL
Intervention: VITAL model
Number of subjects: 0
Study 32050042 — intervention group
Group type: EXPERIMENTAL
Intervention: NLR >4.26
Number of subjects: 1412
Study 32050042 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute neutrophil count >5800/µL
Number of subjects: 1412
Study 32050042 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative neutrophil count >69.7%
Number of subjects: 1412
Study 32050042 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative lymphocyte count ≤17.5%
Number of subjects: 1412
Study 32050042 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute monocytes >810/µL
Number of subjects: 1412
Study 32050042 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute eosinophils ≤200/µL
Number of subjects: 1412
Study 32050042 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative monocytes >6.6%
Number of subjects: 1412
Study 32050042 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative eosinophils ≤2.7%
Number of subjects: 1412
Study 32050042 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative basophils ≤0.6%
Number of subjects: 1412
Study 32050042 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined score including absolute levels of neutrophils, lymphocytes, monocytes and eosinophils
Number of subjects: 1412
Study 32050042 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score of 3–4
Number of subjects: 1412
Study 34967224 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary group‐based pain management programme (standard care plus intervention)
Number of subjects: 136
Study 34967224 — intervention group
Group type: COMPARATOR
Intervention: Standard care (examination by a rheumatologist and/or physiotherapist)
Number of subjects: 136
Study 36153477 — intervention group
Group type: EXPERIMENTAL
Intervention: Handgrip strength measurement
Number of subjects: 120
Study 36153477 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing function measurement
Number of subjects: 120
Study 33068037 — intervention group
Group type: EXPERIMENTAL
Intervention: Omaveloxolone (150mg per day)
Number of subjects: 103
Study 33068037 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 34291993 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine education messaging (n = 362)
Number of subjects: 543
Study 34291993 — intervention group
Group type: COMPARATOR
Intervention: No message control (n = 181)
Number of subjects: 543
Study 34200137 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain neurophysiology education + Therapeutic exercise (PNE + TE)
Number of subjects: 32
Study 34200137 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic exercise (TE)
Number of subjects: 32
Study 36368972 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEK healing abutments
Number of subjects: 11
Study 36368972 — intervention group
Group type: COMPARATOR
Intervention: Titanium healing abutments
Number of subjects: 11
Study 33494785 — intervention group
Group type: EXPERIMENTAL
Intervention: 81 mg aspirin
Number of subjects: 15000
Study 33494785 — intervention group
Group type: COMPARATOR
Intervention: 325 mg aspirin
Number of subjects: 15000
Study 32532483 — intervention group
Group type: EXPERIMENTAL
Intervention: Stopping GDM (SGDM) intervention
Number of subjects: 11
Study 36227598 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD diagnosis
Number of subjects: 393
Study 33782738 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Number of subjects: 48
Study 33782738 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 48
Study 32248760 — intervention group
Group type: EXPERIMENTAL
Intervention: SISTAS intervention (dietary and physical activity intervention)
Number of subjects: 337
Study 32248760 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 337
Study 36243174 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye-tracking analysis
Number of subjects: 49
Study 36243174 — intervention group
Group type: COMPARATOR
Intervention: Conventional observations
Number of subjects: 49
Study 34441791 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck exercise training (NET)
Number of subjects: 66
Study 34441791 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined training (NET + SST)
Number of subjects: 66
Study 34441791 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 66
Study 35334957 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet Adherence Screener (MEDAS)
Number of subjects: 0
Study 35084905 — intervention group
Group type: EXPERIMENTAL
Intervention: Reveal condition (confidence rating after lineup rejection)
Number of subjects: 3346
Study 35084905 — intervention group
Group type: COMPARATOR
Intervention: Standard simultaneous lineup (control condition)
Number of subjects: 3346
Study 33932193 — intervention group
Group type: EXPERIMENTAL
Intervention: Endophytic fungi selected for L‐asparaginase (L‐ASNase) production test (20 isolates).
Number of subjects: 66
Study 33932193 — intervention group
Group type: EXPERIMENTAL
Intervention: Phyllosticta catimbauensis URM 7672 for partial optimisation of L‐ASNase production.
Number of subjects: 66
Study 33894049 — intervention group
Group type: EXPERIMENTAL
Intervention: Video consent
Number of subjects: 30
Study 33894049 — intervention group
Group type: COMPARATOR
Intervention: Written consent
Number of subjects: 30
Study 33206039 — intervention group
Group type: EXPERIMENTAL
Intervention: Precision clinical trial framework including treatment‐targeted enrichment, adaptive treatments, and precise measurement.
Number of subjects: 0
Study 616741616 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-sectional area (CSA) of lumbar muscles
Number of subjects: 209
Study 616741616 — intervention group
Group type: COMPARATOR
Intervention: Demographic and psychosocial variables
Number of subjects: 209
Study 34189995 — intervention group
Group type: EXPERIMENTAL
Intervention: PRC-063 (Extended-Release Methylphenidate)
Number of subjects: 288
Study 34189995 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 288
Study 34078317 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐modified‐rhG‐CSF
Number of subjects: 60
Study 32100161 — intervention group
Group type: EXPERIMENTAL
Intervention: In-plane technique (n=31)
Number of subjects: 65
Study 32100161 — intervention group
Group type: COMPARATOR
Intervention: Out-of-plane technique (n=34)
Number of subjects: 65
Study 32100161 — intervention group
Group type: EXPERIMENTAL
Intervention: In-plane technique
Number of subjects: 65
Study 32100161 — intervention group
Group type: COMPARATOR
Intervention: Out-of-plane technique
Number of subjects: 65